Vivani Medical, Inc.

VANI

NASDAQHealthcareBiotechnology

在 GoAI 中打开

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

37/ 100

GoAI评分

Sell

Trim exposure — unfavorable risk-reward

估值

Expensive

动量

Gaining

情绪

Bullish

风险韧性

Extreme Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Adam Mendelsohn
上市以来: 2014年11月19日
雇员: 42

市场位置

成交量: 10.34万; 0.25× 平均值
平均成交量: 41.52万; 日均成交量
市值: 1.19亿 USD
贝塔: 3.28; 市场参考 1

财务数据

财务快照

估值与收益率

企业价值: 7936.15万 USD
市盈率（TTM）: -3.94×
市净率（TTM）: 6.34×
市销率（TTM）: 0×
EV/EBITDA: -3.03×
盈利收益率: -34.67%
自由现金流收益率: -33.22%
股息率: 0.00%

盈利能力和效率

毛利率: 0.00%
营业利润率: 0.00%
净利润率: 0.00%
净资产收益率: -169.16%
资产收益率: -67.55%
投入资本回报率: -79.68%

财务健康

负债权益比: 0.94×
流动比率: 2.71×

财务报表

损益趋势

营业利润

−2755.6万 USD-11.67%

净利润

−2660.9万 USD-13.30%

项目（USD）	2025财年	2024财年	2023财年	2022财年	2021财年
销货成本	42.4万 USD	—	35.7万 USD	—	—
毛利	−42.4万 USD	—	−35.7万 USD	—	—
研究与开发	1812.6万 USD	1574.5万 USD	1696.8万 USD	1416.9万 USD	1100.2万 USD
销售、一般及管理费用	943万 USD	893.2万 USD	999.7万 USD	537.2万 USD	232.1万 USD
营业费用	2713.2万 USD	2467.7万 USD	2660.8万 USD	2124.1万 USD	1332.3万 USD
折旧和摊销	42.4万 USD	40万 USD	35.7万 USD	38.1万 USD	34.5万 USD
营业利润	−2755.6万 USD	−2467.7万 USD	−2696.5万 USD	−2124.1万 USD	−1332.3万 USD
净利润	−2660.9万 USD	−2348.6万 USD	−2565.2万 USD	−1388.9万 USD	−1277.3万 USD

公司数据更新于 2026年8月24日。

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$4.00

上涨空间 189.86%

过去 12 个月12个月预测最高：US$4.00平均的：US$4.00最低：US$4.00

VANI 消息

globenewswire.com2026年8月13日

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November…

阅读源码

globenewswire.com2026年8月6日

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.

阅读源码

marketbeat.com2026年7月15日

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Vivani Medical NASDAQ: VANI said it is preparing to begin human testing of its semaglutide implant in August and highlighted a recently announced agreement with Novo Nordisk to evaluate the company's implant technology.

阅读源码

globenewswire.com2026年7月14日

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or…

阅读源码

globenewswire.com2026年7月7日

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today…

阅读源码

businesswire.com2026年7月2日

ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical

SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned subsidiary…

阅读源码